Sign In   |   Register
Themed Short Track January - February 2019
Share |

Introducing Themed Short Tracks

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s SHORT TRACK topic is Recent advances in the understanding of Lipoprotein(a), Lp(a):

New knowledge about Lipoprotein(a) is accumulating and the importance of Lp(a) as a risk factor is becoming more evident. In two lectures we present the most recent science about Lp(a): the genetics and the molecular mechanisms in atherosclerosis, the epidemiology and the potential new treatments.

To the SHORT TRACK Recent advances in the understanding of Lipoprotein(a), Lp(a)>>

These presentations are open for EAS members only. Register as an EAS Individual member, and the whole ACADEMY is open for you.

                                                                                                         How to register as an EAS member >>

The case for lipoprotein(a) and cardiovascular disease. 

Dr Pia Kamstrup, Pia R Kamstrup MD, PhD
Head of Department, Dept. of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.

Pia Kamstrup has been one of the leading scientists in the renewed interest in Lp(a). Her studies are based on the epidemiological studies in Copenhagen and have revealed important new information on the genetics of Lp(a) as well as on further understanding of the molecular biology of Lp(a). Furthermore, her studies have clarified the importance of Lp(a) as a risk factor for cardiovascular disease.

                                                                                                         To the presentation>>


Are we ready to test the Lp(a) hypothesis?

Sotirios Tsimikas, Professor of Medicine, University of Californa, San Diego, USA.

Sotirios Tsimikas has made groundbreaking studies on the role of Lp(a) in lipid metabolism, and in his studies, he has increased the understanding of mechanisms for Lp(a) in the development of cardiovascular disease. Furthermore, he has had a leading role in the development of new drugs targeting apolipoprotein(a), a drug that is presently in clinical studies. In this lecture he updates us on the most recent developments on Lp(a)-its role in disease and therapeutic options to lower it.

                                                                                                            To the presentation>>

Membership Software Powered by YourMembership  ::  Legal